DETECTION OF PROTEOLYTIC (C 3-CLEAVING) ACTIVITY ON MOUSE MASTOCYTOMA (P815) CELLS AND OTHER MOUSE-CELL LINES BY FORMATION OF CELL CONTACT WITH C3-CARRYING MOUSE LYMPHOCYTES

被引:13
作者
DIERICH, MP [1 ]
SCHULZ, T [1 ]
YEFENOF, E [1 ]
KLEIN, G [1 ]
机构
[1] KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN
关键词
D O I
10.1002/eji.1830091204
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mouse mastocytoma cells (P815) formed rosettes with normal mouse spleen lymphocytes which had been coated with uncleaved human C 3; this interaction was clearly dependent on the amount of C 3. Lymphocytes treated with C 3 b or buffer alone were ineffective. Formation of cell contact could be inhibited by the presence of protease inhibitors such as diisopropyl fluorophosphate, phenyl methyl sulfonyl fluoride and tosyllysyl chloromethyl ketone. Seven out of 13 different cell lines behaved like P 815 cells. The results strongly suggested that a proteolytic activity on mouse tumor cells led to a cooperation with uncleaved C3 on a carrier cell to connect these two cells. We interpreted these data in analogy to the complement‐dependent bridge formation mechanism (M. P. Dierich and B. Landen, J. Exp. Med. 1977. 146: 1484): uncleaved C3, attached to mouse spleen lymphocytes as carriers, becomes cleaved by enzymes associated with the tumor cells tested; by this cleavage, the labile binding site is released on C3 (nascent C3b) and anchors the C3‐carrying cell to the protease‐ carrying cell; since this labile binding site is short‐lived, this process can be induced by membrane‐associated proteases only. The nature of the proteases and the biological implications of this process are as yet uncertain. Copyright © 1979 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
引用
收藏
页码:928 / 932
页数:5
相关论文
共 16 条
[1]   3RD COMPONENT OF COMPLEMENT (C3) - STRUCTURAL-PROPERTIES IN RELATION TO FUNCTIONS [J].
BOKISCH, VA ;
DIERICH, MP ;
MULLEREBERHARD, HJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (06) :1989-1993
[2]   ISOLATION OF A FRAGMENT (C3A) OF THIRD COMPONENT OF HUMAN COMPLEMENT CONTAINING ANAPHYLATOXIN AND CHEMOTACTIC ACTIVITY AND DESCRIPTION OF AN ANAPHYLATOXIN INACTIVATOR OF HUMAN SERUM [J].
BOKISCH, VA ;
MULLEREB.HJ ;
COCHRANE, CG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1969, 129 (05) :1109-&
[3]  
CAPEL PJA, 1977, PATHOL BIOL, V25, P394
[4]  
COLTEN HR, 1968, J IMMUNOL, V100, P808
[5]   SECOND COMPONENT OF HUMAN COMPLEMENT (C2) - QUANTITATIVE MOLECULAR ANALYSIS OF ITS REACTIONS IN IMMUNE HEMOLYSIS [J].
COOPER, NR ;
POLLEY, MJ ;
MULLEREB.HJ .
IMMUNOCHEMISTRY, 1970, 7 (04) :341-&
[6]  
DIERICH MP, 1977, J IMMUNOL, V118, P2145
[7]   COMPLEMENT BRIDGES BETWEEN CELLS - ANALYSIS OF A POSSIBLE CELL-CELL INTERACTION MECHANISM [J].
DIERICH, MP ;
LANDEN, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 146 (06) :1484-1499
[8]  
GOLDBERG AR, 1974, PROTEINASE INHIBITOR, P631
[9]   INTERACTION BETWEEN 3RD COMPLEMENT PROTEIN AND CELL-SURFACE MACROMOLECULES [J].
LAW, SK ;
LEVINE, RP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (07) :2701-2705
[10]   ACTIVATION OF ALTERNATIVE COMPLEMENT PATHWAY BY HUMAN B-CELL LYMPHOMA LINES IS ASSOCIATED WITH EPSTEIN-BARR VIRUS TRANSFORMATION OF CELLS [J].
MCCONNELL, I ;
KLEIN, G ;
LINT, TF ;
LACHMANN, PJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1978, 8 (07) :453-458